Abstract

BackgroundSoluble fragments of the amyloid precursor protein (APP) generated by α- and β-secretases, sAPPα and sAPPβ, have been postulated as promising new cerebrospinal fluid (CSF) biomarkers for the clinical diagnosis of Alzheimer’s disease (AD). However, the capacity of these soluble proteins to assemble has not been explored and could be relevant. Our aim is to characterize possible sAPP oligomers that could contribute to the quantification of sAPPα and sAPPβ in CSF by ELISA, as well as to characterize the possible presence of soluble full-length APP (sAPPf).ResultsWe employed co-immunoprecipitation, native polyacrylamide gel electrophoresis and ultracentrifugation in sucrose density gradients to characterize sAPP oligomers in CSF. We have characterized the presence of sAPPf in CSF from NDC and AD subjects and demonstrated that all forms, including sAPPα and sAPPβ, are capable of assembling into heteromers, which differ from brain APP membrane-dimers. We measured sAPPf, sAPPα and sAPPβ by ELISA in CSF samples from AD (n = 13) and non-disease subjects (NDC, n = 13) before and after immunoprecipitation with antibodies against the C-terminal APP or against sAPPβ. We demonstrated that these sAPP heteromers participate in the quantification of sAPPα and sAPPβ by ELISA. Immunoprecipitation with a C-terminal antibody to remove sAPPf reduced by ~30% the determinations of sAPPα and sAPPβ by ELISA, whereas immunoprecipitation with an APPβ antibody reduced by ~80% the determination of sAPPf and sAPPα.ConclusionsThe presence of sAPPf and sAPP heteromers should be taken into consideration when exploring the levels of sAPPα and sAPPβ as potential CSF biomarkers.Electronic supplementary materialThe online version of this article (doi:10.1186/1750-1326-10-2) contains supplementary material, which is available to authorized users.

Highlights

  • Soluble fragments of the amyloid precursor protein (APP) generated by α- and β-secretases, Soluble amyloid precursor protein (sAPP) fragment generated after α-secretase cleavage (sAPPα) and sAPP fragment generated after β-secretase cleavage (sAPPβ), have been postulated as promising new cerebrospinal fluid (CSF) biomarkers for the clinical diagnosis of Alzheimer’s disease (AD)

  • We investigate the presence of sAPP forms containing the C-terminal domain (sAPPf) in AD CSF, as well as the oligomerization of sAPP species, to determine how this may affect the measurement of sAPPα/sAPPβ levels by currently available enzyme-linked immunosorbent assay (ELISA) immunoassays

  • Results sAPPf is present in CSF and forms heteromers To determine the presence of sAPPf in human CSF, we first examined samples by Western blotting using different anti-APP antibodies (Figure 1A shows a schematic representation of full-length APP, sAPP fragments generated after secretases processing and the epitopes recognized by different antibodies)

Read more

Summary

Introduction

Soluble fragments of the amyloid precursor protein (APP) generated by α- and β-secretases, sAPPα and sAPPβ, have been postulated as promising new cerebrospinal fluid (CSF) biomarkers for the clinical diagnosis of Alzheimer’s disease (AD). Our aim is to characterize possible sAPP oligomers that could contribute to the quantification of sAPPα and sAPPβ in CSF by ELISA, as well as to characterize the possible presence of soluble full-length APP (sAPPf). The Aβ peptide is generated by processing a large type I transmembrane spanning glycoprotein, the amyloid precursor protein (APP), through the successive action of proteolytic enzymes called secretases. The possibility that sAPP exists in CSF forming oligomers is relevant, since most quantifications of sAPPα and sAPPβ in CSF from Alzheimer’s disease subjects rely on ELISA determinations

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.